Saturday, December 6, 2025

Landing Giants: How Aircraft Tires Handle Extreme Conditions

Known as a jumbo jet, Boeing's B747...

National Security Act Case: A North Korean Defector Spied on a Military Base, Threatening South Korea

A North Korean defector faces a four-year prison term for spying on a radar facility in Jeju and transmitting information to North Korea.

NVIDIA Takes a Breather as Blackwell Chip Demand Holds Strong

NVIDIA's stock dipped slightly, but demand for its Blackwell chip remains strong, indicating healthy market conditions.

Tag: biosimilars

North KoreaKoreaKimSouth KoreaMilitaryAImarketchinaRussia

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

Biosimilars No Longer Second-Best: Highlighting Cost Savings and Improved Patient Access

Biosimilars are becoming standard care, with growing confidence in their safety and efficacy, driven by cost savings and improved accessibility.

Saving Poverty vs Free Trade Society? How Celltrion’s Biosimilar Could Reshape the U.S. Healthcare Market

Professor Metz highlights biosimilars' potential to expand patient access to treatments, emphasizing Omliclo's impact at EADV conference.

Sandoz: Millions of Patients Denied Access to Affordable Enbrel Alternative

Sandoz has filed an antitrust lawsuit against Amgen to challenge patent practices blocking its biosimilar, Erelzi, from market entry.

Europe Moves to Ease Biosimilar Rules, Boosting Asia’s Biopharma Giants

EMA's new guidelines aim to simplify biosimilar development, boosting Samsung Bioepis and Celltrion in Europe's growing market.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.